Myricetin exposure reduces PC differentiation in vitro in primary human B cells
Abstract Background The process of B cell activation and plasma cell (PC) formation involves morphological, transcriptional, and metabolic changes in the B cell. Blocking or reducing PC differentiation is one approach to treat autoimmune diseases that are characterized by the presence of pathogenic...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s10020-025-01068-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571601661460480 |
|---|---|
| author | Shabirul Haque Betty Diamond |
| author_facet | Shabirul Haque Betty Diamond |
| author_sort | Shabirul Haque |
| collection | DOAJ |
| description | Abstract Background The process of B cell activation and plasma cell (PC) formation involves morphological, transcriptional, and metabolic changes in the B cell. Blocking or reducing PC differentiation is one approach to treat autoimmune diseases that are characterized by the presence of pathogenic autoantibodies. Recent studies have suggested the potential of myricetin, a natural flavonoid with anti-inflammatory and antioxidant properties, to block or reduce PC differentiation. Methods Primary human B cells were purified by using a human B cell isolation kit. B cell subsets such as IgG memory B cells, marginal zone B cells (MZ B cells), and naive B cells were isolated by flow cytometry and activated to induce PC differentiation. Quantification of PCs (CD27 + + , CD38 +) was obtained by flow cytometry. The expression of mRNA was measured by qPCR. Ig secretion in culture supernatant was measured by ELISA. Results Myricetin treatment significantly reduced PC differentiation in primary human B cells and all B cell subsets. Myricetin exposure reduced Ig production both IgM and IgG, in culture supernatants at day 5. Myricetin treatment led to augmented BACH2 expression and reduced IRF4, BLIMP1, and XBP1 expression compared to control cultures. Conclusion Myricetin treatment reduced PC differentiation and Ig secretion by primary human B cells. Targeting B cells in this way may be a therapeutic approach for some autoimmune diseases. Graphical Abstract |
| format | Article |
| id | doaj-art-94d43a9b025c4f69a3551538d69490bb |
| institution | Kabale University |
| issn | 1528-3658 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Medicine |
| spelling | doaj-art-94d43a9b025c4f69a3551538d69490bb2025-02-02T12:29:24ZengBMCMolecular Medicine1528-36582025-01-0131111210.1186/s10020-025-01068-xMyricetin exposure reduces PC differentiation in vitro in primary human B cellsShabirul Haque0Betty Diamond1Center for Autoimmune Musculoskeletal and Hematopoietic Diseases, Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Northwell HealthCenter for Autoimmune Musculoskeletal and Hematopoietic Diseases, Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Northwell HealthAbstract Background The process of B cell activation and plasma cell (PC) formation involves morphological, transcriptional, and metabolic changes in the B cell. Blocking or reducing PC differentiation is one approach to treat autoimmune diseases that are characterized by the presence of pathogenic autoantibodies. Recent studies have suggested the potential of myricetin, a natural flavonoid with anti-inflammatory and antioxidant properties, to block or reduce PC differentiation. Methods Primary human B cells were purified by using a human B cell isolation kit. B cell subsets such as IgG memory B cells, marginal zone B cells (MZ B cells), and naive B cells were isolated by flow cytometry and activated to induce PC differentiation. Quantification of PCs (CD27 + + , CD38 +) was obtained by flow cytometry. The expression of mRNA was measured by qPCR. Ig secretion in culture supernatant was measured by ELISA. Results Myricetin treatment significantly reduced PC differentiation in primary human B cells and all B cell subsets. Myricetin exposure reduced Ig production both IgM and IgG, in culture supernatants at day 5. Myricetin treatment led to augmented BACH2 expression and reduced IRF4, BLIMP1, and XBP1 expression compared to control cultures. Conclusion Myricetin treatment reduced PC differentiation and Ig secretion by primary human B cells. Targeting B cells in this way may be a therapeutic approach for some autoimmune diseases. Graphical Abstracthttps://doi.org/10.1186/s10020-025-01068-xMyricetinFlavonoidsB cell differentiationPlasma cellsSLE |
| spellingShingle | Shabirul Haque Betty Diamond Myricetin exposure reduces PC differentiation in vitro in primary human B cells Molecular Medicine Myricetin Flavonoids B cell differentiation Plasma cells SLE |
| title | Myricetin exposure reduces PC differentiation in vitro in primary human B cells |
| title_full | Myricetin exposure reduces PC differentiation in vitro in primary human B cells |
| title_fullStr | Myricetin exposure reduces PC differentiation in vitro in primary human B cells |
| title_full_unstemmed | Myricetin exposure reduces PC differentiation in vitro in primary human B cells |
| title_short | Myricetin exposure reduces PC differentiation in vitro in primary human B cells |
| title_sort | myricetin exposure reduces pc differentiation in vitro in primary human b cells |
| topic | Myricetin Flavonoids B cell differentiation Plasma cells SLE |
| url | https://doi.org/10.1186/s10020-025-01068-x |
| work_keys_str_mv | AT shabirulhaque myricetinexposurereducespcdifferentiationinvitroinprimaryhumanbcells AT bettydiamond myricetinexposurereducespcdifferentiationinvitroinprimaryhumanbcells |